CD8A and neoplasm: Other issues concern the selection of the target; (i) it is clear now that multiple targeting is the strategy to follow, (ii) improvement of the predictor algorithms to select target peptides and test the presence of the epitope in vivo in tumour cells, (iii) choose epitopes that might elicit both CD8+ and CD4+ T-cell responses, (iv) the results indicate that a combination of both shared TAAs and neoantigens should be chosen considering the fact that GBM has a low tumour burden and neoantigens might be few and not optimal.